海正药业(600267.SH)子公司通过药品GMP符合性检查

Core Viewpoint - Haizheng Pharmaceutical (600267.SH) announced that its wholly-owned subsidiary, Haizheng Nantong Company, received a notice from the Jiangsu Provincial Drug Administration regarding the compliance inspection of drug GMP [1] Group 1: GMP Compliance Inspection - The GMP compliance inspection pertains to the active pharmaceutical ingredient Minocycline Hydrochloride, marking the first GMP compliance check prior to its market launch [1] - This inspection is the first for the newly established production line, which has now successfully passed the GMP compliance check [1] Group 2: Financial Investment - The total fixed asset investment in the relevant workshop has reached approximately 99.16 million yuan, with about 86.30 million yuan already completed (unaudited) [1]